AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2022
Feb 5, 2022
32883_dirs_2022-02-04_573f69b8-b64a-4b3f-9294-07e8f3dfe828.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2022-02-02
Reporting Person: STARR CHRISTOPHER M (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-02 | Stock Options | $2.8 | A | 15128 | Acquired | 2032-02-01 | Common Stock (15128) | Direct |
| 2022-02-02 | Restricted Stock Options | $0 | A | 11436 | Acquired | Common Stock (11436) | Direct |
Footnotes
F1: Options vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022.
F2: RSUs vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022.